Hormonal
Weight loss interventions (pharmacological or bariatric) in sarcopenic obesity can improve muscle-specific strength and functional parameters despite absolute muscle mass loss, potentially reversing the sarcopenic obesity diagnosis.
If you are considering weight loss medication for obesity, discuss the potential benefits for muscle function. Even if you lose some muscle mass, your strength and ability to function may improve due to reduced fat in muscles and better metabolism. This can reverse sarcopenic obesity.
One study [48] also reported that improvements in physical function were observed across all age groups... These combined observations indirectly and intriguingly suggest that muscle specific strength could have improved following treatment despite loss of muscle mass [46, 47].
Why this rating
Based on secondary analyses of major trials (STEP-1, SURMOUNT-1) and observational studies, not primary endpoints for muscle gain.
Source
Detecting sarcopenia in obesity: emerging new approaches
G. Gortan Cappellari et al. · Current Opinion in Clinical Nutrition & Metabolic Care · 2024
DOI 10.1097/mco.0000000000001062
More from this paper
- Sarcopenic obesity is a distinct clinical phenotype characterized by high fat mass and low skeletal muscle mass/function, associated with increased risks of frailty, mortality, and metabolic complications, requiring specific diagnostic algorithms (e.g., ESPEN-EASO) for identification.Good
- Resistance-based exercise and protein supplementation are the most consistently effective strategies to treat sarcopenic obesity, with combination therapies showing more positive results.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →